Investing in healthtech to tackle Indonesia’s greatest challenges

The COVID-19 pandemic has exposed critical gaps in Indonesia’s healthcare infrastructure, revealing structural and systemic shortcomings that will require scalable solutions. Change doesn't happen overnight, particularly for the healthcare sector, which consists of multiple intertwined industries with strict regulatory oversight. But precisely because the industry is highly regulated, regulations play a huge role in shaping trends.

PathGen raises funding from East Ventures and Royal Group Indonesia, making early disease detection and precision medicine more accessible

PathGen or PathGen Diagnostik Teknologi, an Indonesia-based healthcare biotechnology startup specializing in molecular testing solutions, has raised funding from East Ventures and Royal Group Indonesia